Lytix Biopharma developes proprietary oncolytic peptides as a novel immune therapy to fight cancer.

Lytix' lead candidate, LTX-315, is developed for intratumoral treatment of solid tumors turning cold tumors hot.

 

 

Lytix´ development strategy is to develop product candidates to be used and combined within immuno-oncology. Today, the majority of Lytix’ projects relate to the use of the Company’s clinical candidate LTX-315. Furthermore, the Company has a promising pipeline of new oncolytic compounds, such as LTX-401, for deep-seated tumors.

 

ONGOING STUDY:

An open-label phase II single-centre study investigating the safety and efficacy of LTX-315 and adoptive T-cell therapy in patients with advanced/metastatic soft tissue sarcoma.

 

DESIGN

Phase II, open-label and single-center study.

The patient population that will be evaluated in this study have advanced/metastatic disease and will have received one (or possibly multiple) lines of treatment for advanced/metastatic disease.

 

OBJECTIVES

Primary objectives:

           To determine the safety of LTX-315 as part of adoptive T-cell therapy in advanced/metastatic soft tissue sarcoma
           To determine the ability of LTX-315 to induce T-cell infiltration prior to TIL expansion.

Secondary objectives:

           To assess the ability to expand CD8+ T-cells from tumour tissues
           To assess the anti-tumour effect of LTX-315 as part of adoptive T-cell therapy in advanced/metastatic soft tissue sarcoma